Sign In
Free Newsletter
Novo Nordisk chair touts OTC future for Wegovy as top investor tightens grip
New Novo Nordisk chair Lars Rebien Sorensen plans to add pharma and OTC expertise after a board shake-up that sparked governance concerns.
Metsera falls after accepting up to $10 billion offer from Pfizer
Pfizer wins a $10 billion deal for weight-loss drugmaker Metsera, ending its bidding war with Danish rival Novo Nordisk.
Pfizer to buy Metsera in $5B obesity drug deal
Pfizer will acquire Metsera for nearly $5B, boosting its push into obesity treatments with potential oral and injectable drugs.
Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition
FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company’s focus on growth opportunities in obesity and diabetes medications. The restructuring, which would eliminate 11% of the company’s workforce, aimed to reduce organizational [&hellip[...]
